Get the Daily Brief
Latest Biotech News
Obesity drug breakthroughs and next-gen GLP-1 competition
Eli Lilly escalated the obesity race with new conference and trial reporting on eloraTZP, an amylin-incretin combination. Lilly said the regimen delivered up to 23.3% weight loss in adults with...
Regulatory setbacks and reversals in fibrosis: Bristol Myers and FDA scrutiny
Bristol Myers Squibb is facing renewed confidence questions for its fibrosis program after reported liver-related safety concerns. The company acknowledged a limited number of liver injury events,...
CAR-T and cell therapy scale-up bottlenecks
CAR-T therapy manufacturing is hitting a key operational limit: scaling remains the bottleneck even after the field secured multiple clinical successes. A new industry-focused report highlights...
Cell therapy resubmissions after FDA reversals: Atara and Pierre Fabre’s Ebvallo
Atara Biotherapeutics and Pierre Fabre Pharmaceuticals said they are resubmitting Ebvallo (tabelecleucel) to the FDA after the agency delivered additional rejection signals. The therapy targets...
Bio-manufacturing in space: Varda’s $251M Series D
Varda Space Industries raised $251 million in a Series D round to advance pharmaceutical manufacturing in space. The company positions microgravity as a platform for producing drug substances that...
Antibody developability data collaboration
Ginkgo Datapoints and Apheris launched a new Antibody Developability Consortium designed to improve earlier prediction of manufacturability and developability risks. The collaboration aims to...
Weight-loss AI: Growth in GLP-1 compounded use raises scrutiny
New reporting and analysis suggests that many patients using GLP-1 drugs such as Ozempic and Wegovy may be receiving compounded copies rather than brand-name products. Photo checks and pattern...
Huntington gene therapy durability concerns: UniQure’s AMT-130 update
UniQure’s Huntington’s gene therapy AMT-130 continues to show disease progression slowing four years after implantation, but the company’s benefit magnitude appears to have declined versus earlier...
US regulatory framework and evidence standards: EMA pushes back on rigid trial-count logic
The European Medicines Agency argued that drug developers should focus on generating robust evidence rather than adhering to a fixed number of clinical trials. In an editorial, EMA executives and...
Immune biology—chemotherapy-driven senescence and senolytics rationale
Researchers reported a mechanism linking doxorubicin chemotherapy to accelerated heart aging in male mice, with CD47—the “don’t eat me” protein—emerging as a driver of chemotherapy-induced...
US regulatory push to accelerate AI-enabled clinical trials
The US Department of Health and Human Services (HHS) announced SURPASS, a new five-year program to speed and expand clinical trials by integrating artificial intelligence and computational models....
FDA review momentum for next-generation MS oral therapy
The FDA has started a review of Roche’s multiple sclerosis pill fenebrutinib, according to the report. The filing represents a notable regulatory step for a BTK inhibitor program positioned in...
Bristol Myers fibrosis-drug readout clouds as patient death emerges
Bristol Myers Squibb’s upcoming readout for its fibrosis candidate admilparant faces renewed scrutiny after the company disclosed a limited number of liver-related safety events, including a...
AstraZeneca deepens Summit Therapeutics cancer strategy with $2B equity investment
AstraZeneca agreed to invest $2 billion in Summit Therapeutics, taking an equity stake and setting up clinical collaborations aimed at advancing ivonescimab, a PD-1/VEGF bispecific. The...
Obesity pipeline stakes rise as Lilly and peers post high-impact weight-loss efficacy
Eli Lilly reported what it framed as top-tier weight-loss results for retatrutide in people with obesity and type 2 diabetes, highlighting outcomes from its Phase 3 program TRIUMPH-2. In the 12 mg...
UniQure Huntington gene-therapy follow-up raises durability questions
UniQure’s Huntington’s disease gene therapy AMT-130 continued to slow progression after four years, but the company disclosed that the magnitude of benefit has waned compared with prior analyses....
China biopharma IP risk surfaces as Beam sues for base-editing theft
Beam Therapeutics filed litigation alleging a former scientist stole confidential information and used it to co-found a Chinese company tied to a competing gene-editing program. Beam alleges that...
Regulatory and manufacturing pressure drives Cell-and gene therapy reroute at Atara and Pierre Fabre
Pierre Fabre Pharmaceuticals and Atara Biotherapeutics resubmitted Ebvallo (tabelecleucel) to the FDA after the agency previously rejected the therapy twice. The resubmission targets a fatal...
Fertility market attention grows, but biotech’s operational focus remains trial execution and access
A new analysis highlighted opportunities in the fertility and reproductive health market, framing how demand growth and innovation may translate into investable segments for biopharma-adjacent...
CAR-T economics and manufacturing bottlenecks remain central as companies pursue scalable delivery
Ongoing reporting underscores that CAR-T therapy economics and access are constrained not only by efficacy but by manufacturing capacity, donor-to-donor variability, and multi-step GMP workflows....